Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study
Bernhard Manger,1 Falk Hiepe,2 Matthias Schneider,3 Margitta Worm,4 Peter Wimmer,5 Eva-Maria Paulus,5 Andreas Schwarting6 1University Hospital Erlangen, Med Clinic III Polyclinic, Erlangen, 2Rheumatology, University Hospital Charité, Campus Mitte, Berlin, 3Policlinic of Rheumatology, Hein...
Main Authors: | Manger B, Hiepe F, Schneider M, Worm M, Wimmer P, Paulus EM, Schwarting A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-07-01
|
Series: | Clinical and Experimental Gastroenterology |
Online Access: | http://www.dovepress.com/impact-of-switching-from-mycophenolate-mofetil-to-enteric-coated-mycop-peer-reviewed-article-CEG |
Similar Items
-
Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?
by: Kyle M. Gardiner, et al.
Published: (2018-11-01) -
Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats
by: Yichen Jia, et al.
Published: (2018-07-01) -
Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis
by: Seung Woon Park, et al.
Published: (2016-06-01) -
Mycophenolate mofetil and atherosclerosis
by: Z S Alekberova, et al.
Published: (2009-10-01) -
Mycophenolate mofetil alters the antioxidant status in duodenum of rats: Implication for silymarin usage in mycophenolate mofetil induced gastrointestinal disorders
by: Sanaz Sheikhzadeh, et al.
Published: (2013-06-01)